Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Hershey, PA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Hershey, PA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Lancaster, PA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Lancaster, PA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Dallas, TX
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Houston, TX
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
San Antonio, TX
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Charlottesville, VA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Fairfax, VA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Fairfax, VA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Richmond, VA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Herston,
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Herston,
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Lutherville-Timonium, MD
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Lutherville-Timonium, MD
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Saint Louis, MO
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
The Bronx, NY
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
The Bronx, NY
Click here to add this to my saved trials
Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study
NUTRItional Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double Blind, Placebo-controlled Trial of the Motilin Receptor Agonist GSK962040. The NUTRIATE Study
Status: Enrolling
Updated:  11/9/2017
GSK Investigational Site
mi
from
Aurora, CO
Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study
NUTRItional Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double Blind, Placebo-controlled Trial of the Motilin Receptor Agonist GSK962040. The NUTRIATE Study
Status: Enrolling
Updated: 11/9/2017
GSK Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study
NUTRItional Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double Blind, Placebo-controlled Trial of the Motilin Receptor Agonist GSK962040. The NUTRIATE Study
Status: Enrolling
Updated:  11/9/2017
GSK Investigational Site
mi
from
Augusta, GA
Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study
NUTRItional Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double Blind, Placebo-controlled Trial of the Motilin Receptor Agonist GSK962040. The NUTRIATE Study
Status: Enrolling
Updated: 11/9/2017
GSK Investigational Site
mi
from
Augusta, GA
Click here to add this to my saved trials
Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study
NUTRItional Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double Blind, Placebo-controlled Trial of the Motilin Receptor Agonist GSK962040. The NUTRIATE Study
Status: Enrolling
Updated:  11/9/2017
GSK Investigational Site
mi
from
Louisville, KY
Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study
NUTRItional Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double Blind, Placebo-controlled Trial of the Motilin Receptor Agonist GSK962040. The NUTRIATE Study
Status: Enrolling
Updated: 11/9/2017
GSK Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials
Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study
NUTRItional Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double Blind, Placebo-controlled Trial of the Motilin Receptor Agonist GSK962040. The NUTRIATE Study
Status: Enrolling
Updated:  11/9/2017
GSK Investigational Site
mi
from
Louisville, KY
Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study
NUTRItional Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double Blind, Placebo-controlled Trial of the Motilin Receptor Agonist GSK962040. The NUTRIATE Study
Status: Enrolling
Updated: 11/9/2017
GSK Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials
Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study
NUTRItional Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double Blind, Placebo-controlled Trial of the Motilin Receptor Agonist GSK962040. The NUTRIATE Study
Status: Enrolling
Updated:  11/9/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study
NUTRItional Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double Blind, Placebo-controlled Trial of the Motilin Receptor Agonist GSK962040. The NUTRIATE Study
Status: Enrolling
Updated: 11/9/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study
NUTRItional Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double Blind, Placebo-controlled Trial of the Motilin Receptor Agonist GSK962040. The NUTRIATE Study
Status: Enrolling
Updated:  11/9/2017
GSK Investigational Site
mi
from
Randwick,
Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study
NUTRItional Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double Blind, Placebo-controlled Trial of the Motilin Receptor Agonist GSK962040. The NUTRIATE Study
Status: Enrolling
Updated: 11/9/2017
GSK Investigational Site
mi
from
Randwick,
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Arizona Digestive Health
mi
from
Mesa, AZ
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Arizona Digestive Health
mi
from
Mesa, AZ
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Arizona Digestive Health
mi
from
Phoenix, AZ
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Arizona Digestive Health
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Arizona Digestive Health
mi
from
Sun City, AZ
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Arizona Digestive Health
mi
from
Sun City, AZ
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Gastroenterology Associates,P.A.
mi
from
Little Rock, AR
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Gastroenterology Associates,P.A.
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Valley View Internal Medicine
mi
from
Garden Grove, CA
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Valley View Internal Medicine
mi
from
Garden Grove, CA
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
High Desert Gastroenterology
mi
from
Lancaster, CA
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
High Desert Gastroenterology
mi
from
Lancaster, CA
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
University of Southern California Medical Center
mi
from
Los Angeles, CA
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
University of Southern California Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Facey Medical Foundation
mi
from
Mission Hills, CA
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Facey Medical Foundation
mi
from
Mission Hills, CA
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Medical Associates Research Group
mi
from
San Diego, CA
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Medical Associates Research Group
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
University of California at San Francisco (PARENT)
mi
from
San Francisco, CA
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
University of California at San Francisco (PARENT)
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
HCP Clinical Research LLC
mi
from
Torrance, CA
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
HCP Clinical Research LLC
mi
from
Torrance, CA
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Ventura Clinical Trials
mi
from
Ventura, CA
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Ventura Clinical Trials
mi
from
Ventura, CA
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
University of Colorado
mi
from
Aurora, CO
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Innovative Clinical Research
mi
from
Lafayette, CO
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Innovative Clinical Research
mi
from
Lafayette, CO
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Connecticut Gastroenterology Institute
mi
from
Bristol, CT
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Connecticut Gastroenterology Institute
mi
from
Bristol, CT
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Medical Research Center of Connecticut, LLC
mi
from
Hamden, CT
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Medical Research Center of Connecticut, LLC
mi
from
Hamden, CT
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Connecticut GI PC Research Division
mi
from
Hartford, CT
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Connecticut GI PC Research Division
mi
from
Hartford, CT
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Yale University
mi
from
New Haven, CT
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Florida Center for Gastroenterology
mi
from
Largo, FL
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Florida Center for Gastroenterology
mi
from
Largo, FL
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Galiz Research
mi
from
Miami Springs, FL
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Galiz Research
mi
from
Miami Springs, FL
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Advance Medical Research Center
mi
from
Miami, FL
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Advance Medical Research Center
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Cordova Research Institute
mi
from
Miami, FL
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Cordova Research Institute
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Sanitas Research
mi
from
Miami, FL
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Sanitas Research
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Gastroenterology Group of Naples
mi
from
Naples, FL
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Gastroenterology Group of Naples
mi
from
Naples, FL
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
GCRM
mi
from
Orlando, FL
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
GCRM
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Center For Digestive Health
mi
from
Orlando, FL
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Center For Digestive Health
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
East Coast Institute for Research LLC
mi
from
Saint Augustine, FL
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
East Coast Institute for Research LLC
mi
from
Saint Augustine, FL
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Cleveland Clinic Florida - Weston
mi
from
Weston, FL
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Cleveland Clinic Florida - Weston
mi
from
Weston, FL
Click here to add this to my saved trials
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated:  11/9/2017
Shafran Gastroenterology Center
mi
from
Winter Park, FL
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
Status: Enrolling
Updated: 11/9/2017
Shafran Gastroenterology Center
mi
from
Winter Park, FL
Click here to add this to my saved trials